Brainscape's Knowledge GenomeTM

Browse over 1 million classes created by top students, professors, publishers, and experts.


See full index

Oncology > Oral Chemotherapy > Flashcards

Oral Chemotherapy Flashcards

1
Q

Thalidomide, Lenalidomide, and Pomalidomide are what kind of oral chemo agents?

A

Immunomodulators
Anti-angiogenics
IMiDs

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
2
Q

Why would patients prefer oral chemo?

A

Convenience
Less invasive
Ease of administration
Sense of empowerment

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
3
Q

Why oral over IV chemo?

A

Less invasive
Convenient
Self-administered
May be payable through Medicare Part D

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
4
Q

Advantages of oral chemo from a healthcare professional standpoint

A

oral admin can provide prolonged drug exposure which may be important for drugs with schedule-dependent efficacy

potential to reduce the use of healthcare resources for inpatient and ambulatory patient care services

may provide better QOL

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
5
Q

Challenges of oral chemo therapy

A

many drug-drug and drug-food interactions
patients with hx of dysphagia, odynophagia, severe n/v
patient adherence
less opportunity for healthcare professionals for pt interaction (pt edu, tox management, assessment on dz response)
shift of responsibility from provider to pt
drug cost ($$$)

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
6
Q

How do IMiDs work?

A

Selectively inhibit secretion of pro-inflammatory cytokines
Stimulates anti-CD3 stimulated Tcells
Inhibits trophic signals to angiogenic factors in cells
Induces cell cycle arrest and cell death in myeloma cells

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
7
Q

Which anti-angiogenic does not need renal adjustment?

A

Thalidomide

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
8
Q

Which immunomodulator needs hepatic adjustment?

A

Pomalidomide

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
9
Q

What are the 3 adverse effects to immunomodulators/anti-angiogenics/IMiDs?

A

Neuropathy, DVT/PE, Myelosuppression (neutropenia)

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
10
Q

What is the major warning related to immunomodulators: Thaliodmide, Lenalidomide, Pomalidomide?

A

Pregnancy Category X - REMS needed

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
11
Q

Everolimus blocks which important factor?

A

VEGF (vascular endothelial growth factor) and HIF-1 (hypoxia-inducible factor)

mTOR kinase inhibitor with antiproliferative and antiangiogenic properties

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
12
Q

Adverse effects related to Everolimus

A

Metabolic Syndrome (hi-cholesterol, glucose, TG), Electrolyte abnormalities (decrease in K, Ca, Phos, Mg, HCO3), fatigue/malaise, edema

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
13
Q

Major DDIs with Everolimus

A

CYP3A4 inducers/inhibitors

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
14
Q

Which alkylating agent is available IV and PO?

A

Cyclophosphamide and Temozolomide

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
15
Q

Cyclophosphamide has what adverse effects?

A

Hemorrhagic cystitis (dose-dependent), alopecia, N/V (dose-dependent), sterility

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
16
Q

What patient education pts are important for cyclophosphamide?

A

Do not administer at bedtime to minimize risk of bladder irritation
Take during or after meals
INCREASE fluid INTAKE while on therapy to decrease risk of hemorrhagic cystitis

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
17
Q

MOA of Temozolomide

A

A prodrug**: hydrolyzed to active form MTIC which exerts cytotoxic effects

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
18
Q

Adverse Effects of Temozolomide

A

Non-specific: fatigue, N/V, constipation, lymphocytopenia

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
19
Q

Patient education for Temozolomide

A

Absorption is affected by food, so consistently take with or without food
May take on empty stomach at bedtime to reduce N/V
Anti-emetics** are recommended that prevent N/V (for higher doses > 75 mg/m2/day)
PCP Prophylaxis** (in pts receiving concomitant radiotherapy, longer dosing regimens, or concomitant steroids)

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
20
Q

Selective estrogen receptor modulator (SERM) oral chemotherapy agent

A

Tamoxifen

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
21
Q

ADRs for Tamoxifen

A

Mood changes, vasodilation, edema, nausea, vasomotor (hot flashes), vaginal discharge - bone and tumor pain
BBW: VTE and increased risk of uterine malignancies

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
22
Q

MOA for Abiraterone

A

Blocks CYP17 (involved in androgen synthesis) and inhibits cortisol production

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
23
Q

ADRs for Abiraterone

A

(Since cortisol precursor is still available, it causes the following): hypokalemia, fluid retention, hypertension, vasomotor side-effects, increased LFTs, hypertriglyceridemia

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
24
Q

PK/PD of Capecitabine

A

Prodrug that converted into active metabolite 5-FU**

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
25
Q

ADRs of Capecitabine

A

HFS, diarrhea, mucositis/stomatitis

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
26
Q

Patient education of Capecitabine

A

Usually administered in 2 divided doses taken 12 hours apart
Doses should be taken with water within 30 min after a meal
Avoid prolonged sun exposure (use sunscreen)

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
27
Q

Largest group of oral chemotherapy agents

A

Tyrosine Kinase Inhibitors

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
28
Q

What is the ending of Tyrosine Kinase Inhibitors?

A

“-nibs” small molecule: used in both solid tumors and heme cancers

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
29
Q

Class side effects of Tyrosine Kinase Inhibitors from all inhibitions (VEGF, EGFR, BCR-ABL)

A

Diarrhea**, Fatigue, Rash

30
Q

Class side effects with Tyrosine Kinase Inhibitors for VEGF inhibition

A

HFS**, HTN, hemorrhage

31
Q

Class side effects with Tyrosine Kinase Inhibitors for EGFR inhibition

A

Acneiform rash**, nail changes, hair changes

32
Q

Class side effects with Tyrosine Kinase Inhibitors for BCR-ABL inhibition

A

Fluid retention**

33
Q

FLT-3 inhibitors

A

Midostaurin, Gilteritinib

34
Q

Midostaurin ADR of FLT-3 Inhibitors

A

Nausea, Mucositis, Myelosuppression**, Diarrhea, Hyperglycemia, Edema, Fatigue, Headache

35
Q

Gilteritinib ADR of FLT-3 Inhibitors

A

Hypertriglyceridemia, Increased LFTs, headache, fatigue, edema, hyperglycemia, nausea, mucositis, diarrhea, myelosuppression

36
Q

CDK-4/6 Inhibitors (3): Cyclin-dependent Kinase inhibitors

A

Palbociclib, Abemaciclib, Ribociclib

37
Q

MOA of CDK-4/6 Inhibitors

A

Interrupting hormone signals that stimulate proliferation (usually CDK-4/6 are up-regulated: they are associate with uncontrolled cell proliferation)

38
Q

ADRs with Palbociclib, Abemaciclib, Ribociclib (CDK-4/6 Inhibitors)

A

Diarrhea (Abemaciclib), Neutropenia (Palbociclib), Fatigue, Nausea, Increased LFTs

39
Q

PARP Inhibitors

A

Olaparib, Niraparib, Rucaparib, Talazoparib (-parib)

40
Q

MOA of Olaparib, Niraparib, Rucaparib, Talazoparib (-parib)

A

PARP Inhibitor (Poly (ADP-ribose) polymerase enzyme inhibitor; PARP-1/2 are involved in detecting DNA damage, and promoting repair; therefore, inhibition results of apoptosis

41
Q

PARP Inhibitors are not super well tolerated, and usually not the most effective dose. What are the ADRs of Olaparib, Niraparib, Rucaparib, Talazoparib (-parib)?

A

Myelosuppression (Olaparib), Nausea (Olaparib, Niraparib, Rucaparib), Headache, Fatigue

42
Q

IDH-1/2 Inhibitors

A

Ivosidenib, Enasidenib

43
Q

MOA for IDH-1/2 inhibitors: Ivosidenib, Enasidenib

A

Inhibitor of mutant isocitrate dehydrogenase 1/2 enzymes. Mutated IDH 1/2 leads to increased levels of 2-hydroxyglutarate, which is responsible for impaired hematopoietic differentiation, typically seen in leukemia cells. SO by blocking the mutant IDH-1/2, restore proper bone marrow differentiation

44
Q

ADRs for IDH-1/2 Inhibitors: Ivosidenib, Enasidenib

A

Hyperbilirubinemia & Myelosuppression (Enasidenib**), Differentiation Syndrome (think MOA), N/D

45
Q

Why is differentiation syndrome a side effect of IDH-1/2 Inhibitors?

A

MOA is to prevent impaired differentiation, so it restores proper differentiation. This can cause a hyper-proliferation of myeloid cells = excessive inflammatory response.
Causes “sepsis looking” response: hypotension, fever, dyspnea, hypoxia, peripheral edema, pleural or pericardial effusion, and multi-organ dysfunction

46
Q

Management of Differentiation syndrome with Ivosidenib, Enasidenib

A

Hold therapy and initiate glucocorticoid therapy and monitor hemodynamics
Can resume when sxs done

47
Q

PI3K inhibitors

A

Idelalisib, Duvelisib, Copanlisib (-lisib)

48
Q

MOA of PI3K Inhibitors: Idelalisib, Duvelisib, Copanlisib (-lisib)

A

Inhibition of delta isoform of phosphatidylinositol-3 kinase will lead to apoptosis
PI3K-delta is highly expressed in malignant lymphoid B-cells, and when PI3K is activated, it will cause survival + proliferation + angiogenesis –> development of cancer when dysregulated

49
Q

ADRs for Idelalisib, Duvelisib, Copanlisib (-lisib)

A

Fatigue, Diarrhea, Nausea, Myelosuppression

50
Q

Proteasome inhibitors

A

Ixazomib

51
Q

MOA for Ixazomib (Proteasome Inhibitors)

A

Reversible inhibition of chymotrypsin-like activity of beta-5 subunit of the 20s proteasome leading to cell cycle arrest and apoptosis

Proteasome are important for protein degradation and expression [—– Blocking proteasome will lead to accumulation of misfolded proteins to promote cell death

52
Q

ADR for Proteasome Inhibitors (Ixazomib)

A

Peripheral neuropathy**, eye disease, peripheral edema, diarrhea, nausea, myelosuppression (thrombocytopenia, neutropenia)

53
Q

BCL-2 Inhibitors

A

Venetoclax

54
Q

MOA of Venetoclax (BCL-2 Inhibitor)

A

Selective inhibition of anti-apoptotic BCL-2 protein which is over-expressed in leukemic cells –> causes apoptosis of B cells

BCL-2 also mediates tumor cell survival and has been associated with tumor resistance to chemotherapy on the mitochondrial membrane

55
Q

ADRs for Venetoclax (BCL-2 Inhibitor)

A

TLS**, fatigue, edema, diarrhea, AST elevation, myelosuppression, myalgia

56
Q

Describe TLS associated with Venetoclax (BCL-2 Inhibitor)

A

Oncologic emergency characterized by metabolic disturbances that results from the massive lysis of tumor cells that release their contents into the bloodstream

Sxs: hyperuricemia, hyperkalemia, hyperphosphatemia, hypocalcemia

Prophylaxis required during venetoclax initiation/ramp-up phase

57
Q

What is the prophylaxis for TLS during venetoclax initiation/ramp-up phase?

A

AML: If WBC >=25,000, adequate hydration + anti-hyperuricemic
CLL: all levels of tumor burden requires hydration (PO/IV) + anti-hyperuricemic

58
Q

HDAC Inhibitors

A

Vorinostat, Panobinostat (-inostat)

59
Q

MOA of Vorinostat, Panobinostat (-inostat) : HDAC Inhibitors

A

Histone deacetylase (HDAC) inhibition resulting in increased acetylation of histone proteins

Accumulation of acetylated histones and other proteins induces cell cycle arrest and apoptosis

Histones are structural support for DNA. Usually you need to deacetylase to remove the groups. But if it is blocked = cell death

60
Q

ADR of HDAC Inhibitors: Vorinostat, Panobinostat (-inostat)

A

Fatigue, peripheral edema, nausea, diarrhea, muscle weakness, myelosuppression

61
Q

Clinical Pearls to remember for HDAC Inhibitors: Vorinostat, Panobinostat (-inostat)

A

Obtain EKG prior to therapy initiation to verify that QTc <450 ms (for Panobinostat)

For Vorinostat, Panobinostat (-inostat) prior to treatment, start:

  • baseline ANC >=1500
  • platelet >= 100k
  • *due to myelosuppression ADR**
62
Q

Hedgehog Pathway inhibitors

A

Vismodegib, Sonidegib, Glasdegib (-degib)

63
Q

MOA of Vismodegib, Sonidegib, Glasdegib (-degib): Hedgehog pathway inhibitors

A

Hedgehog pathway regulates cell growth and differentiation in embryogenesis
Mutation in the hedgehog pathway results to unrestricted proliferation of basal cells of the skin
Hedgehog inhibitors bind to Smoothened Homologue (SMO), which is the transmembrane protein involved in hedgehog-signal transduction –> cell death

64
Q

ADR for Vismodegib, Sonidegib, Glasdegib (-degib): Hedgehog pathway inhibitors

A

Increased CPK, Fatigue, Nausea, Diarrhea, Decrease appetite

65
Q

Which drug class is known for acneiform rash? (Think MOA)

A

EGFR Inhibitors (TKIs) - highest for all grades Afatinib

66
Q

Describe acneiform rash cause by EGFR inhibitors

A

on face, back, chest
first 2-4 weeks: first presents with acne-like rash
peaks at weeks 4-6: post inflammatory effects, dry skin, fissure
decreases after 6-8 weeks: paronychia (a skin infection around the fingernails or toenails)

67
Q

How to decrease incidence rate of acneiform rash with EGFR inhibition

A

Start one of these WITH therapy for total duration 6-8 weeks (also they are associated with treatment for grades of rash):
Topical [Grade 1]: Hydrocortisone 1% cream + moisturizing emollients + sunscreen (SPF 15+)
Systemic [Grade 2]: Doxycycline 100 mg PO BID or Minocycline 100 mg PO daily
[Grade 3/4]: Prednisone 0.5 mg/kg IV

68
Q

Onset and symptoms of HFS from multi-targeted tyrosine kinase inhibitor

A

Onset: 2-4 weeks of therapy (1st month)
Symptoms: erythema, paresthesia, blisters in the palms and soles followed by thick hyperkeratotic, tender, lesions
Dose-dependent effect: Resolution if therapy is held

69
Q

Pharmacologic/Non-Pharmacologic Management of HFS

A
70
Q

Diarrhea is caused by which drugs?

A

Capecitabine + TKIs

71
Q

Management for Diarrhea with Capecitabine and TKIs

A

Hold oral chemotherapy if increase of >= 4 stools/day over baseline
Increase fluid intake
Loperamide (Imodium): cancer treatment-induced 4mg followed by 2mg q4hrs or **after each loose stool (no maxdose) OR 4mg follow by 2mg every q2hrs
Diphenoxylate/Atropine 2.5/0.025 mg (Lomotil): when imodium fails, adjunct therapy 2.5-5mg PO QID until symptoms control

Oncology (6 decks)

Brainscape helps you reach your goals faster, through stronger study habits.
© 2024 Bold Learning Solutions. Terms and Conditions